About 100 guests from 36 countries met on the XVIII. MetaSystems Distributor Meeting (DM) in November to exchange experiences and to get to know new trends and developments at MetaSystems.
XL BCR/ABL1 plus
Translocation/Dual Fusion Probe
- Order Number
- Package Size
- 100 µl (10 Tests)
The XL BCR/ABL1 plus probe is specific for the t(9;22). The orange labeled probe hybridizes to an extended region spanning the ABL1 locus on 9q34, and a green labeled probe hybridizes specifically to extended regions spanning the BCR gene on 22q11. The probe is designed as a dual-color, dual-fusion assay.
Probe map details based on UCSC Genome Browser GRCh37/hg19. Map components not to scale.
Chronic myelogenous leukemia (CML) is genetically characterized by the presence of the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR/ABL gene fusion on the derivative chromosome 22, called the Philadelphia (Ph) chromosome. The same translocation can also be found in acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) with some variation in the breakpoint region. Glivec® (imatinib mesylate) treatment targeting the BCR/ABL active tyrosine kinase has become a major drug in treating CML, gastrointestinal stromal tumors, and other cancers.
- Chronic Myelogenous Leukemia and Myeloproliferative Neoplasms (CML/MPN)
- Acute Lymphoblastic Leukemia (ALL)
- Acute Myelogenous Leukemia (AML)
Two green (2G) and two orange signals (2O).
Aberrant Cell (typical results):
One green (1G), one orange (1O), and two green-orange fusion signals (2GO).
- Dewald et al (1998) Blood 91:3357-3365
- Huntly et al (2003) Blood 102:1160-1168
- Primo et al (2003) Leukemia 17:1124-1129